TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMT stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ritu Baral has given her Buy rating due to a combination of factors that highlight Sagimet Biosciences, Inc.’s promising future prospects. The initiation of a first-in-human Phase 1 trial for the next-generation FASN inhibitor TVB-3567 in acne, along with a Phase 1 combination trial with denifanstat and resmetirom in MASH, indicates a strong pipeline with potential for significant clinical advancements. These trials are expected to yield topline data in the first half of 2026, which could further validate the company’s innovative approaches.
Moreover, Sagimet Biosciences, Inc. has a solid financial position, with $125 million in cash expected to support operational expenses through the completion of the current Phase 1 trials. Despite reporting a net loss in the third quarter of 2025, the company’s increased R&D expenditure reflects its commitment to advancing its clinical programs. The strategic focus on developing treatments for acne and MASH, combined with the potential for successful trial outcomes, underpins the Buy rating assigned by Ritu Baral.
In another report released on November 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $29.00 price target.